From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer - Scorecard - MDSpire
Advertisement
From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer
Clinical Scorecard: Advancements in Understanding Gemcitabine Resistance Mechanisms in Bladder Cancer: From Molecular Pathways to Clinical Applications
At a Glance
Category
Detail
Condition
Key Mechanisms
Gemcitabine resistance mechanisms include impaired drug uptake, enhanced DNA damage repair, and epithelial-mesenchymal transition; most findings are still in preclinical or retrospective validation stages.
Target Population
Care Setting
Key Highlights
Gemcitabine remains central in the treatment of NMIBC and MIBC.
Resistance to gemcitabine can be categorized into early, intermediate, and late stages.
Most mechanistic findings related to gemcitabine resistance are still in preclinical or retrospective validation stages.
Emerging resistance can be detected dynamically during treatment.
Guideline-Based Recommendations
Diagnosis
Utilize imaging and clinical evaluation to assess bladder cancer progression.
Management
Gemcitabine is recommended for intravesical therapy in BCG-naive and BCG-unresponsive NMIBC patients.
For MIBC, gemcitabine combined with cisplatin is the standard of care.
Monitoring & Follow-up
Monitor for signs of resistance and treatment response through longitudinal paired clinical samples.
Risks
Primary non-response or acquired resistance to gemcitabine can limit treatment efficacy.
Patient & Prescribing Data
Patients diagnosed with bladder cancer, particularly those undergoing treatment with gemcitabine.
Gemcitabine is often used in combination with other therapies, including immunotherapy and antibody-drug conjugates.
